Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
1305 East Houston Street , San Antonio, TX, 78205, US
Scorpius BioManufacturing is a U.S. biologics CDMO providing cGMP manufacturing, bioanalytical, and process development services for mammalian and microbial programs. Scorpius specializes in working with start-ups and emerging biotechs, giving small-volume programs the attention and flexibility they deserve.
As the number of new companies in biopharma continues to grow, so does their demand for outsourcing at every level of biopharmaceutical development.
Released By Scorpius BioManufacturing
A global pandemic magnified the need for more biologics manufacturing capacity. Capacity, however, isn’t the whole story.
What is a culture of quality, and how do you know if a biologics CDMO can earnestly make this claim?
Samir Lakhashe, Director, Bioanalytical Sciences, discusses assay categorization, the company's growing toolbox, predictions for the future, and more.
The demand for biologic drugs continues to grow at a steady 12–14% annually.
100 subject matter experts were surveyed from smaller biotech innovators to gain insight into the dynamics and drivers of the current biologics market.
Clinical manufacturing of cGMP-compliant mammalian cell culture processes is a complex and resource-intensive effort that presents several challenges.
Biologics process development is an active undertaking that seeks continuous improvement along the entire length of the drug development timeline.
A look at a CDMO’s value throughout a monoclonal antibody (mAb) therapeutic's lifecycle.
The value biologics CDMOs provide their innovator customers has changed radically in recent years, presenting new questions that must be answered.
The biologics CDMO selected for a given product or program is critical to an innovator’s ability to deliver a drug product safely, on time, and on budget.
When selecting a biologics CDMO partner—whether you need mammalian or microbial capabilities—the decision-making process follows a similar process.
Why Fina Biosolutions partnered with Scorpius Biomanufacturing for cGMP production of Ecocrm® (CRM197)
While crafting a RFP to capture the information innovators need to select a CDMO partner has always been critical; it has grown increasingly complicated.
The partnership includes recovery and downstream process optimization, analytical method implementation and phase-appropriate validation, and more.
Flexible, responsive, customized services for taking a program from R&D into the clinic, using American facilities and American sourced materials and equipment.
Delivering consistent and scalable mammalian-derived products, Scorpius uses its American facilities to advance your drug from R&D to the clinic and beyond.
Scorpius’ team has extensive experience in E. coli microbial biomanufacturing, including hard-to-work-with inclusion bodies.
Utilizing American-made equipment and reagents, Scorpius develops custom assays to profile your molecule and test your clinical trial samples.
Process development & cGMP contract manufacturing for biologics and cell therapies.
Papzimeos is the first and only approved therapy to treat adults with Recurrent Respiratory Papillomatosis.
By: Rachel Klemovitch
Meeting Global Injectable Demand
Released By Rovi Pharma Industrial Services
Platform and product releases span OPUS, MINT, POET, and SPI.
Will expand domestic active pharmaceutical ingredient (API) production in the U.S.
By: Charlie Sternberg
New alliance is dedicated to advancing lipid nanoparticle (LNP) technology and accelerating the development of next-generation therapeutics.
The site is also expanding its High Potency Active Pharmaceutical Ingredient and Antibody Drug Conjugate capacity.
Avista will leverage Forge’s FUEL platform to manufacture AAV for AVST-101, Avista’s lead gene therapy to treat patients with X-linked retinoschisis (XLRS).
Certifies ElevateBio’s compliant and scalable manufacturing capabilities for advanced therapies using U.S. and E.U. commercial-level evaluation standards.
The new facility designs, develops and manufactures research-grade pDNA materials to support the cell and gene therapy field.
Sartorius supports commercialization and joint development of solutions based on Nanotein’s NanoSpark platform.
AVTOZMA IV now aligns with all indications approved for ACTEMRA IV in the United States.
Strategic expansion is designed to advance gene therapy development and manufacturing.
CEO Dr. Johannis Willem van Vliet will leave the company shortly as the company transitions to a CDMO.
Becomes one of the largest global suppliers of Pegfilgrastim biosimilar.
Why cutting-edge cancer therapies remain out of reach for too many families—and what needs to change.
By: Emilee Kudla
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
